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III Definition of the
Metabolic Syndrome
Results from a population-based
survey
Our objective was to evaluate the di-agnostic proficiency of the WorldHealth Organization (WHO) and
the National Cholesterol Education Pro-
gram (NCEP)-III definitions (1,2) for the
metabolic syndrome in a Mexican nation-
wide, population-based survey. Details of
the sampling procedures have been pre-
viously described (3). The population was
composed of 2,158 men and women aged
20–69 years sampled after a 9- to 12-h
fasting period. For the WHO criteria, in-
sulin resistance was diagnosed if a non-
diabetic case had fasting insulin concen-
trations 126 pmol/l (21 U/ml) (75th
percentile in Mexican adults). The age-
adjusted prevalence was 13.61% for the
WHO criteria (n  268) and 26.6% for
the NCEP-III definition (n  574). After
excluding patients with diabetes, the prev-
alence was 9.2 and 21.4%, respectively.
The agreement between the definitions
was assessed in 1,969 subjects; 189 cases
were eliminated due to the lack of a urine
sample.
The number of abnormal cases was
lower using the WHO criteria. Only 237
of the 545 subjects (43.4%) who fulfilled
the NCEP criteria were diagnosed as af-
fected using the WHO definition. Just 16
of 253 cases (6.3%) detected by the WHO
definition did not fulfill the NCEP defini-
tion. The agreement between the criteria
was moderate (  0.507). On the other
hand, the subjects diagnosed using the
WHO recommendations had a worse
profile than the cases detected by the
NCEP-III definition only—they had a
higher BMI and higher non-HDL choles-
terol, triglyceride, and glucose concentra-
tions. The demonstration of insulin
resistance among the nondiabetic popu-
lation caused the lack of agreement in 202
of the 242 cases that fulfilled the NCEP
definition but failed the WHO criteria.
Other reasons for disparity were the
higher thresholds used by the WHO cri-
teria; these differences explained the lack
of agreement in 66 of the 152 cases with
diabetes.
In conclusion, the prevalence of the
metabolic syndrome is influenced by the
selection of the diagnostic criteria. The
WHO criteria identified a lower number
of cases than the NCEP-III definition.
These differences were explained mainly
by the inclusion of abnormally high insu-
lin concentrations as a diagnostic crite-
rion. However, the presence of insulin
resistance may help to identify patients
more severely affected (4).
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W e read with interest the article byRossing et al. (1) in the January2002 issue of Diabetes Care. We
had previously assessed the effect of com-
plete blockade of the renin-angiotensin
system (RAS) in patients with advanced
diabetic nephropathy (type 2 diabetes)
and severe proteinuria (2). To do so, we
studied 10 patients on prior treatment
with ACE inhibitors at recommended
doses, to which 50 mg/day of Losartan
was added.
After 3 months of the combined ther-
apy, urinary protein excretion decreased
from a mean of 6.9 (95% CI 4.3–9.6) to
5.8 g/24 h (3–8.6) (P  0.025) and, with
the exception of two patients, was re-
duced in all cases. The proteinuria/
urinary creatinine ratio also decreased
from 7.6 (4.2–11.05) to 6.0 g/g (3.2–8.7)
(P  0.02). In one patient in which pro-
teinuria did not vary, the proteinuria/
creatinine ratio also decreased, reflecting
a possible error in the quantification of
the patient’s proteinuria instead of a lack
of response to the treatment. The glomer-
ular filtration rate (GFR), calculated using
the mean of creatinine and urea clearance,
a measurement that avoids the overesti-
mation that creatinine clearance produces
in the GFR (3), decreased slightly from
21.5  8.5 to 19.9  7.8 ml/min (P 
0.158). An interesting decrease in total
cholesterol from 6.21  1.03 to 5.33 
1.27 mmol/l (P  0.036) was observed.
Total proteins, serum albumin, protein
intake, and mean arterial pressure (MAP)
were not significantly modified. Only one
patient had hyperkaliemia (from 5.1 to
7.2 mmol/l). No secondary effects were
seen in the other patients. At 12 months of
treatment, proteinuria decreased to 3.4
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g/24 h and the proteinuria/urinary creat-
inine ratio to 3.6. GFR decreased by 0.83
ml  min1  month1 in the first 6
months and only fell by 0.18 ml  min1 
month1 during the last 6 months. Two
patients received the combined treatment
for 42 months. During the first 18
months, proteinuria decreased by 74 and
67% in each case; GFR fell by 0.5 and 1 ml
 min1  month1, respectively; and MAP
did not vary in the first case and decreased
from 123 to 101 mmHg in the second.
Over the following 24 months, protein-
uria was 1 g/24 h in both cases and GFR
increased in one patient by 2 ml/min and
did not vary in the other patient. In this
period, MAP and protein intake remained
unvaried.
The data of Rossing et al. confirm that
in the short term, complete blockade of
the RAS system produces an antiprotein-
uric effect and affords a greater renopro-
tective effect since proteinuria is an
important risk factor for kidney disease
progression (4). Although our data can
only be considered as observational find-
ings, they do allow us to intuit that this
renoprotective effect, due to the dual
blockade of the RAS, will be increased
when treatment is prolonged to medium
or long term. Moreover, the observed de-
crease in total cholesterol levels would
contribute to reducing both the progres-
sion of the nephropathy, since elevated
serum cholesterol levels act as an inde-
pendent promoter of progression in dia-
betic nephropathy (5), and the high
cardiovascular risk seen in this type of
patient.
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A cute cholinergic muscarinic block-ade with pirenzepine (PIR) inducesdose-related reductions in plasma
glucose (PG) and plasma insulin (PI) after
mixed meals in normal individuals and in
type 2 diabetic and polycystic ovary syn-
drome patients (1–2). Altogether, 24 pa-
tients with type 2 diabetes (12 male and
12 female) with a fasting plasma glucose
10 mmol/l were studied for the effects
of PIR (50 mg b.i.d.) given for 2 weeks on
fasting and postprandial plasma glucose
and insulin concentrations. Patients on
ACE inhibitors or thiazide diuretics were
excluded.
Oral hypoglycemics were stopped at
least 2 weeks before treating the patients
with either PIR or placebo in a random-
ized, cross-over, double-blind fashion
with a 2-week washout period between
the two treatment arms. At the beginning
(day 1) and end (day 14) of each treat-
ment period, blood was sampled over
12 h, during which time the patients re-
ceived three standard meals. The sched-
uling for blood sampling, meals, and PIR
administration is illustrated in Fig. 1. The
primary outcome measure for the study
was the difference between PIR- and pla-
cebo-treated fasting plasma glucose on
day 14 of the study. Statistical analysis
was performed using the paired Student’s
t test.
There was a significant reduction in
the fasting PG levels on day 14 (PIR) com-
pared with day 14 (placebo) (mean reduc-
tion  SD, 1.2  1.6 mmol/l, 95% CI
0.5–1.9, P  0.002 by paired Student’s t
test) (Fig. 1). There were trends for reduc-
tion in the glucose area under the curve
and highest postprandial peaks for day 14
(PIR) compared with day 14 (placebo),
but the results did not reach statistical sig-
nificance. There was no significant differ-
ence in fasting plasma insulin levels.
The mechanism through which PIR
produces its effect on PG is unknown.
Possible hypotheses are the obliteration of
an increased hypothalamic cholinergic
tone responsible for increased 24-h growth
hormone (GH) secretion, particularly
suppression of nocturnal GH secretion,
which we and others (3,4) have previ-
ously demonstrated. Another possibility
is the effect of PIR on gastrointestinal hor-
mones through its anticholinergic effect,
which may affect PG levels indirectly (5).
In conclusion, PIR caused a statisti-
cally significant reduction in fasting PG
levels compared with placebo after 2
weeks of therapy, but there was no corre-
sponding increase in insulin levels. PIR
may be an effective drug in the treatment
of type 2 diabetes.
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T ype 2 diabetes is characterized byboth insulin resistance and an in-creased cardiovascular mortality
(1). Elevated plasma total homocysteine
levels are an independent risk factor for
cardiovascular disease (2). Also, in pa-
tients with type 2 diabetes, elevated
plasma total homocysteine levels are asso-
ciated with an increased risk of cardiovas-
cular disease and an increased mortality
(3,4).
It is well known that insulin resis-
tance is aggravated by chronic hypergly-
cemia. This hyperglycemia-induced
insulin resistance is reversed by treat-
ment, resulting in a prolonged period of
euglycemia (5).
Although in animal studies evidence
was found that hyperinsulinemia and/or
insulin resistance increased total homo-
cysteine levels (6), in humans the relation
between insulin resistance and total ho-
mocysteine levels is unclear, in both
healthy subjects (7–12) and patients with
type 2 diabetes (13–16). In patients with
type 2 diabetes, a positive association be-
tween insulin resistance and total homo-
cysteine levels was reported (13), but this
finding was not reproduced (14). Fur-
thermore, in patients with type 2 diabe-
tes, a positive association between the
degree of metabolic control and total ho-
mocysteine levels was reported (15,16).
We hypothesized that if insulin resis-
tance is associated with elevated homo-
cysteine levels, thereby providing another
explanation for the increased cardiovas-
cular disease in type 2 diabetes, then ho-
mocysteine levels will decrease after
amelioration of hyperglycemia-induced
insulin resistance and associated meta-
bolic abnormalities.
Here, we report the results of an in-
tervention study (17). Eight obese type 2
diabetic patients (aged 53  13 years,
HbA1c 12.0  1.7%, BMI 38  5.8 kg/
m2) with severe insulin resistance (subcu-
taneous insulin dose, four-dose insulin
regimen 1.92  0.66 units  kg1  day1)
were studied before and after a period of
28  5 days of intravenous insulin treat-
ment. Intravenous insulin treatment re-
sulted in euglycemia. Before and after
intervention, insulin sensitivity was as-
sessed by a hyperinsulinemic-euglycemic
clamp. Fasting plasma total homocys-
teine, HbA1c, and lipid concentrations
were measured on the days of the clamps.
Also, 24-h urine creatinine excretion was
investigated before and after intervention.
Plasma total homocysteine levels
were measured with a high-performance
liquid chromatography method accord-
ing to Fiskerstrand (18,19) with some
modifications. Because all variables were
normally distributed, statistical analyses
of differences were performed by paired
Student’s t test. P  0.05 was considered
Figure 1—Day curve of plasma glucose (A) and insulin (B) concentrations after 14 days of PIR
(50 mg b.i.d.) (F) and placebo (E). The vertical continuous lines represent the time when piren-
zepine was administered and the interrupted lines represent the times at which breakfast, lunch,
and dinner were given.
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significant. Results are given as the
mean  SD.
After a 4-week period of intravenous
insulin treatment resulting in an euglyce-
mic period of 17  4 days, insulin sensi-
tivity improved since body glucose
uptake, measured by clamp, increased
(12.7  5.7 before vs. 22.4  8.8 mol 
kg1  min1 after euglycemia, P 
0.0005) and the intravenous insulin dose
required for achieving and maintaining
euglycemia decreased (1.7  0.9 before
vs. 1.1  0.6 units  kg1  day1 after
euglycemia, P  0.005). Metabolic con-
trol improved; HbA1c decreased substan-
tially (12.0  1.7 before vs. 8.9  1.2%
after euglycemia, P  0.0001); total cho-
lesterol decreased (5.40  1.09 before vs.
4.50  1.10 mmol/l after euglycemia, P 
0.05); and triglycerides tended to de-
crease (4.34  3.32 before vs. 1.91 
0.69 mmol/l after euglycemia, P  0.06).
These results are described in detail else-
where (17). Plasma total homocysteine
levels were similar before and after im-
proved insulin sensitivity (total homocys-
teine levels 8.5  2.4 before vs. 9.2  3.5
mol/l after euglycemia, P  0.5). Urine
creatinine excretion was similar before
and after euglycemia (15.0  4.8 before
vs. 12  4.3 mol/24 h after euglycemia).
This intervention study shows that
despite amelioration of hyperglycemia-
induced insulin resistance and improved
metabolic control, plasma total homocys-
teine concentrations did not decrease.
Homocysteine levels, measured in these
patients with type 2 diabetes, were actu-
ally within the normal range of healthy
subjects (2).
Our study is the first intervention
study to investigate the relation between
insulin resistance and plasma total homo-
cysteine levels. To date only cross-
sectional studies have been performed
(13–15), which are more susceptible for
confounding by other metabolic factors.
Also in contrast to previous reports
(8,9,11,12,14,15), we studied insulin
sensitivity by clamp, the gold standard.
We conclude that amelioration of hy-
perglycemia-induced insulin resistance
does not change plasma total homocys-
teine levels. These data refute the hypoth-
esis that homocysteine levels are
influenced by insulin resistance and by
the degree of metabolic control, at least in
the patients we studied. Therefore, these
results do not support elevated homocys-
teine levels as an explanation for the link
between insulin resistance and the in-
creased risk of cardiovascular disease in
type 2 diabetes.
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D espite significant improvements intherapy over the last decade, theprognosis of nephropathic type 2
diabetic patients continues to be poor (1).
In recent antihypertensive intervention
studies performed in type 2 diabetic pa-
tients with overt nephropathy, the mean
5-year mortality rate was 20%. In the
irbesartan study published by Lewis et al.
(2), the mean death rate after 54 months
ranged from 15 (irbesartan group) to
16.3% (placebo group). Similar data were
obtained in the losartan study published
by Brenner et al. (3). These results might
lead to false conclusions concerning the
overall mortality of all unselected type 2
diabetic patients with overt nephropathy.
In the irbesartan study, major excretion
criteria were congestive heart failure
(New York Heart Association [NYHA]
class III or worse) and cardiovascular
events within the last 3 months.
In accordance with the irbesartan
study, in 1996 we recruited all nephro-
pathic type 2 diabetic patients who were
treated at that time in our hospital and/or
in the outpatient care unit and who ful-
filled the inclusion criteria of the study
(serum creatinine 1.0–3.0 mg/dl in fe-
male and 1.3- 3.0 mg/dl in male patients,
as well as protein excretion 1.0 g/24-h
urine), without considering the usual ex-
clusion criteria. We recruited 46 nephro-
pathic type 2 diabetic patients (aged 61 
8 years, 26 women and 20 men, diabetes
duration 17  4 years), and we prospec-
tively studied their progression of diabetic
nephropathy and the 5-year mortality rate.
Cardiovascular disease was present in
43%, while 28% had heart failure (NYHA
class III and higher). Of patients, 36% had
exclusion criteria according to the irbe-
sartan study. All patients underwent eval-
uations in our outpatient unit (n  24) or
at the offices of their general physicians in
at least 6-month intervals over an obser-
vation period of 5 years. The following
parameters were routinely measured: cre-
atinine in serum and 24-h urine, creati-
nine clearance (calculated), protein in
24-h urine, HbA1c, and blood pressure.
The three end points of the study were
doubling of serum creatinine levels, end-
stage renal disease, or death. Patients were
also divided into those with and without
heart failure, and 5-year mortality rates
were assessed in both groups.
Serum creatinine had doubled in 37%
of patients over 60 months, compared
with 22% within 54 months in the irbe-
sartan study. The percentage of patients
who reached end-stage renal disease was
26% in our patients and 16.7% in the
irbesartan study. During the period of ob-
servation, mean HbA1c level in our pa-
tients was 7.6  1.0%, while their mean
blood pressure was 139  11/80  8
mmHg. In the irbesartan study, the mean
blood pressure at visits after baseline was
similar, with 140/77 mmHg in the irbe-
sartan group and 144/80 mmHg in the
placebo group.
The overall 5-year mortality of all of
our diabetic patients was 33%. Five-year
mortality rates were 57% in patients with
heart failure (NYHA III or IV) and 22%
(P  0.05) in those without heart failure.
In comparison with the data of the inter-
vention studies, the mortality of our ne-
phropathic type 2 diabetic patients
without heart failure was similar to that of
the selected patients in the irbesartan
study. In contrast, survival was signifi-
cantly lower in patients with heart failure,
and as a consequence, the overall mortal-
ity of all unselected type 2 diabetic pa-
tients with overt nephropathy was also
higher than that registered in the inter-
vention studies. There were no significant
differences at baseline visit in creatinine
clearance (139  31 vs. 134  32 ml 
min1  1.73 m2) and urinary protein
(2.4  1.3 vs. 2.3  1.2 g/24 h) in the
groups with and without chronic heart
failure, respectively. The mean blood
pressure during the observation period
was approximately the same in both
groups (140  12 vs. 138  11 mmHg).
Twenty-eight percent of the patients with
and 25% of those without heart failure
reached end-stage renal disease. Our re-
sults are in agreement with those of Short
(4), who found, at a mean follow-up of
5.3 years, a mortality rate of 37% in ne-
phropathic type 2 diabetic patients com-
pared with just 8% in a nonnephropathic
group. Multivariate Cox regression anal-
yses confirmed a fivefold excess risk for
cardiovascular mortality in type 2 diabetic
patients with overt nephropathy. Angio-
tensin II blockers have shown effective
cardiovascular protection in type 2 dia-
betic patients (5).
In conclusion, the real mortality rate
of all unselected type 2 diabetic patients
with overt nephropathy and mild-to-
moderate renal insufficiency is much
higher than the mortality of nephropathic
type 2 diabetic patients selected for anti-
hypertensive studies. The difference be-
tween outcome in studies versus “real life”
is mainly due to the fact that patients with
heart failure are excluded from studies,
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T ype 1 diabetes is characterized bythe presence of insulitis and auto-antibodies, at least in the earlier
course of the disease. It is well known that
HLA locus confers strong genetic suscep-
tibility to the disease. Imagawa et al. (1)
described a unique subtype of type 1 di-
abetes that shows a rapid and fulminant
onset of the disease but lacks evidence of
insulitis and autoantibodies. Although
the etiology of this unique subtype of type
1 diabetes is unclear at present, Tanaka et
al. (2) very recently reported that specific
HLA-DQ genotypes may be associated
with this subtype of type 1 diabetes. Here,
we report clinical characteristics of sub-
jects with type 1 diabetes of a rapid and
fulminant onset who were collected from
the registration of type 1 diabetes in our
institution.
We identified 19 type 1 diabetic sub-
jects showing an acute and abrupt onset
of diabetes (duration of hyperglycemic
symptoms 6  3 days [mean  SD],
range 1–10) accompanied by low HbA1c
levels (6.8  0.9%, 5.4–8.2). The sub-
jects consisted of 11 men and 8 women
aged 38  17 years (range 16–66) with
BMI of 22.2  3.2 kg/m2 (17.1–27.7).
Family history of diabetes (possibly type 2
diabetes) was recorded in three subjects
(16%). Among eight women, four mani-
fested diabetes during gestation (n  2) or
just after delivery (n  2). History of pre-
ceding upper respiratory infection was
noted in nine subjects (47%). Despite
short duration of subjective symptoms
and low HbA1c levels, their initial concen-
trations of plasma glucose was as high as
34.1  13.2 mmol/l (range 13.6–72.4),
indicating a fulminant onset of diabetes.
In fact, 14 subjects showed diabetic keto-
acidosis at their initial presentation (arte-
rial pH 7.14  0.17, 6.80–7.34), and the
remaining five had marked ketosis and
hyperglycemia. GAD autoantibodies,
measured by commercial RIA kits (Cos-
mic Corporation, Tokyo) (3), were nega-
tive in 18 of the 19 subjects (1.5 units/
ml), but a single subject showed a weakly
positive level (5.6 units/ml). Insulinoma-
associated protein 2 (IA2) autoantibody
and anti-thyroperoxidase and -thyroglob-
ulin antibodies were negative in all sub-
jects. Fasting serum level and urinary
excretion of C-peptide were decreased to
0.10  0.07 nmol/l (0–0.26) and 2.2 
2.1 mol/day (0.2– 6.9), respectively,
and they did not show any signs of remis-
sion of insulin dependency during the ob-
servation period.
As for HLA status, HLA-DRB1-DQB1
genotypes were determined and com-
pared with those in autoantibody (GAD
and/or IA2 autoantibodies)-positive sub-
jects with significant type 1A diabetes
(n  87) derived from our registration.
F requency o f HLA-DRB1*0405-
DQB1*0401 haplotype in a homozygous
manner was significantly higher in the
rapid-onset group (5 of 19, 26%) than the
type 1A group (4 of 87, 5%, P  0.009 by
Fisher’s exact probability). The frequency
was also far higher than that of nondia-
betic Japanese subjects reported in the lit-
erature (1 of 84, P  0.001 [2] and 6 of
157, P  0.003 [4]). Frequency of other
susceptible haplotypes (DRB1*0405-
DQB1*0401 in a heterozygous manner
and DRB1*0901-DQB1*0303 in a ho-
mozygous manner) (4) did not differ be-
tween the rapid-onset group and type 1A
group (data not shown).
In our experience, homozygous HLA-
DRB1*0405-DQB1*0401 haplotype con-
fers genetic susceptibility to rapid-onset
type 1 diabetes in Japanese, consistent
with the recent report by Tanaka et al. (2).
Frequency of GAD autoantibodies was ac-
tually low in this subgroup of type 1 dia-
betes (1,2), but a single subject showed a
positive result at the onset of diabetes.
There was also a case report in which
GAD autoantibodies turned positive 1
year after the fulminant onset of type 1
diabetes (5). Tanaka et al. (6) also dem-
onstrated presence of insulitis in a case of
rapid-onset type 1 diabetes. Collectively,
it is suggested that rapid-onset type 1 di-
abetes could share autoimmune etiology
with type 1A diabetes (7). Of interest is
that half of the female patients developed
diabetes during or just after pregnancy.
There have been many studies reporting
altered immune response during preg-
nancy (8,9), and pregnancy is considered
to be a precipitating factor for type 1 dia-
betes (10). We hypothesize that altered
immune response to unknown stimulus
may be causative of rapid and aggressive
	-cell loss, together with the genetic sus-
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While diabetes is associated withincreased risk of perioperativestroke among subjects who un-
dergo carotid endarterectomy (1–3),
women and minorities have been gener-
ally underrepresented in such trials (4).
The North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET)
was a randomized study of 2,885 eligible
patients with carotid stenosis 70% who
received either medical (n  1,449) or
surgical therapy (n  1,436 patients) (3).
The median study age was 66 years, and
93% of study subjects were white. Ap-
proximately 30% of NASCET subjects
were female, and 22% had a history of
diabetes, which was almost always type 2
diabetes (3). The study showed that end-
arterectomy safely and efficaciously re-
duced the risk of stroke in symptomatic
patients with higher-grade carotid arterial
stenosis when compared with medical
therapy (3). Multivariate analysis indi-
cated an increased risk of perioperative
stroke in subjects with a history of diabe-
tes (relative risk [RR] 2.0, 95% CI 1.2–
3.1) (3). Because NASCET had a relatively
high proportion of both female and dia-
betic subjects, we addressed the hypoth-
esis that there would be differences
between diabetic men and women with
respect to the risk of peri- and postoper-
ative complications. Subjects were subdi-
vided by surgical or medical therapy and
then subdivided again by sex and diabetes
history. End point data regarding strokes
and deaths were collected.
Diabetic men had a significantly in-
creased risk of stroke or death 30 days
postendarterectomy compared with non-
diabetic men (RR 2.3, 95% CI 1.4–3.7),
with no difference between diabetic and
nondiabetic women (1.1, 0.5–2.4). Fur-
thermore, diabetic men had a signifi-
cantly increased risk of stroke 3 years
postendarterectomy compared with non-
diabetic men (RR 1.9, 95% CI 1.3–2.8),
again with no difference between diabetic
and nondiabetic women (1.0, 95% CI
0.6–1.9). However, at 3 years postran-
domization, diabetic men who received
medical treatment had no increased risk
of stroke compared with nondiabetic men
(RR 0.7, 0.5–1.1). In contrast, at 3 years
postrandomization, diabetic women who
received medical treatment had a signifi-
cantly increased risk of stroke compared
with nondiabetic women (1.7, 1.1–2.8).
The results support the emerging im-
pression of sex-related differences among
diabetic subjects with respect to vascular
disease (5,6). Perioperative neurological
morbidity of carotid endarterectomy is
mainly due to embolization at the time of
clamping or clamp release, ischemia dur-
ing clamping of extracranial arteries, and
intracerebral hemorrhage (7). There has
been a steady decrease in postoperative
morbidity among patients who undergo
carotid endarterectomy as a result of both
improved surgical technique and patient
selection (7). Baseline clinical attributes
are also helpful predictors of postopera-
tive mortality and morbidity from stroke
(3). Our analysis suggests that among di-
abetic subjects who undergo carotid end-
arterectomy, there may be sex-related
differences in postoperative neurological
morbidity. As with any post hoc subgroup
analysis, the results should be interpreted
cautiously and must be replicated in other
studies. However, if these findings are
confirmed, it might be appropriate to
consider sex and diabetes status in strate-
gies to optimize the management of pa-
tients with carotid disease (8).
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In 2000 we developed the Diabetes Em-powerment Scale (DES) to measure thepsychosocial self-efficacy of people
with diabetes. The original questionnaire
contained 37 items representing eight
conceptual dimensions (i.e., assessing the
need for change, developing a plan, over-
coming barriers, asking for support, sup-
porting oneself, coping with emotion,
motivating oneself, and making diabetes
care choices appropriate for one’s priori-
ties and circumstances). Using factor
analyses the questionnaire was reduced to
the current 28-item DES (
  0.96) con-
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taining three subscales (1). The three sub-
scales are: 1) managing the psychosocial
aspects of diabetes with 9 items (
 
0.93), 2) assessing dissatisfaction and
readiness to change with 9 items (
 
0.81), and 3) setting and achieving goals
with 10 items (
  0.91). In addition to
providing an overall assessment of dia-
betes-related psychosocial self-efficacy,
the three subscales of the DES allow for an
examination of its underlying components.
To allow for a brief overall assessment
of diabetes-related psychosocial self-
efficacy, we developed an eight-item short
form of the DES (the DES-SF). The
DES-SF was created by choosing the item
from the remaining 28 items with highest
item to subscale correlation from each of
the original eight conceptual domains.
The reliability of the DES-SF using the
original dataset was 
  0.85. We have
subsequently administered the DES-SF to
229 subjects in a new study. The reliabil-
ity of the DES-SF using the data from the
new sample was 
  0.84. The content
validity of the DES-SF was supported in
the new study by the fact that both
DES-SF scores and HbA1c levels changed
in a positive direction after the 229 sub-
jects completed a 6-week problem-based
patient education program (2). The
change in DES-SF scores and HbA1c levels
were not correlated, suggesting that these
two measures vary independently.
These data provide preliminary evi-
dence that the DES-SF is a valid and reli-
able measure of overall diabetes-related
psychosocial self-efficacy. The DES and
the DES-SF, scoring information, and
permission to use them can be down-
loaded from the Michigan Diabetes Re-
search and Training Center web site at:
www.med.umich.edu/mdrtc.
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Patients With Type 2
Diabetes
P revious studies have demonstratedthat oxidative stress is associated notonly with hyperglycemia and hyper-
tension but also with the metabolic syn-
drome and cadiovascular disease (1–3).
Adrenomedullin (AM) is a novel va-
sorelaxant peptide isolated from human
pheochromocytoma (4,5). Oxidative
stress enhances AM production from en-
dothelium and vascular smooth muscle
cells in vitro (6,7). However, whether ox-
idative stress is associated with circulating
levels of AM in vivo is unknown. In the
present study, we evaluated the relation-




currently regarded as the most reliable
marker for the assessment of oxidative
stress in humans) (8,9) and AM in normal
subjects and hypertensive patients with
type 2 diabetes.
This study comprised 17 hyperten-
sive patients with type 2 diabetes (15 men
and 2 women, age 47.3  3.0 years
[mean  SE], BMI 23.2  0.8 kg/m2, fast-
ing plasma glucose 8.2  0.5 mmol/l,
HbA1c 9.9  0.5%, fasting serum insulin
30.6  3.0 pmol/l, systolic blood pres-
sure 150.2  3.4 mmHg, and diastolic
blood pressure 76.5  2.2 mmHg) and
18 normal subjects (17 men and 1
women, age 43.0  1.9 years, BMI 23.8 
0.4 kg/m2, fasting plasma glucose 5.1 
0.2 mmol/l, fasting serum insulin 31.2 
3.6 pmol/l, systolic blood pressure
126.8  2.2 mmHg, and diastolic blood
pressure 79.8  1.6 mmHg). All subjects
were nonsmokers. Hypertensive patients
with type 2 diabetes were diagnosed at a
local clinic 3.0  0.2 years before the be-
ginning of this study. All patients were
treated with diet (1,440–1,720 kcal/day
and sodium restriction 304 mmol/day)
and exercise (walking 10,000 steps/day);
none of them were receiving any kind of
drug. Their blood glucose and blood pres-
sure were in good control (HbA1c 6.5%,
systolic blood pressure 140 mmHg, and
diastolic blood pressure 90 mmHg)
during the initial several months. How-
ever, thereafter the blood glucose and
blood pressure of the patients gradually
increased (HbA1c 8%, systolic blood
pressure 140 mmHg, and diastolic
blood pressure 90 mmHg) because of
overeating and inactivity. They were re-
ferred to our clinical department for con-
trol of hyperglycemia and hypertension.
None of them had evidence of micro- or
macroangiopathy. Informed consent was
obtained from all subjects before the be-
ginning of the study. Plasma levels of free
8-epi-PGF2
 were measured using a
commercially available enzyme immuno-
assay kit (Cayman Chemical, Ann Arbor,
MI). The detection limit of this assay was
1.5 pg/ml, and the intra- and interassay
coefficients of variation were 7.5 and
9.2%, respectively. AM in plasma samples
was measured using a commercially avail-
able immunoradiometric assay kit
(Shionogi Pharmaceuticals, Osaka, Ja-
pan). The detection limit of this assay was
2 fmol/ml, and the intra- and interassay
coefficients of variation were 7.0 and
6.9%. Serum insulin was measured using
an immunoradiometric assay kit (Insulin
Riabead II kit; Dainabot, Tokyo). The in-
tra- and interassay coefficients of varia-
tion of the assay were 1.9 and 2.0%. In
addition, we measured blood pressure in
supine position after a 5-min rest.
Both plasma levels of 8-epi-PGF2

and AM were significantly increased in
hypertensive patients with type 2 diabetes
compared with normal subjects (8-epi-
PGF2
 48.6  8.6 vs. 11.9  1.3 pg/ml,
P  0.05; AM 14.8  0.7 vs. 12.4  0.2
fmol/ml, P  0.02). The plasma levels of
8-epi-PGF2
 were proportionally corre-
lated with AM (r  0.696, P  0.01) in
only hypertensive patients with type 2 di-
abetes. Significant positive correlations
were observed between plasma levels of
Letters
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8-epi-PGF2
 (r  0.540, P  0.05) or
AM (r  0.875, P  0.001) and systolic
blood pressure in patients with type 2 di-
abetes.
This is the first report that demon-
strated a relationship between oxidative
stress and AM in vivo. The mechanism by
which plasma levels of 8-epi-PGF2
 cor-
relate with AM and the cellular source of
AM remain unknown. Previous studies
have shown that oxidative stress stimu-
lates secretion of AM from endothelium
and vascular smooth muscle cells and that
AM mRNA expression is increased by ac-
tivation of the nuclear factor-B pathway
(6,7). Increased AM secretion from endo-
thelium and vascular smooth muscle may
influence the plasma levels of AM. On the
other hand, Shimosawa et al. (10) re-
ported that endogenous AM may protect
from organ damage by inhibiting oxida-
tive stress production. Increased AM lev-
els may compensate for oxidative stress–
induced vasoconstriction and thus may
play a protective role against organ injury.
Adrenal medulla and pancreatic islets
may also be a source of AM (4,11). Fur-
ther study is needed to clarify the source
of plasma AM and the mechanism of cor-
relation between oxidative stress and AM.
In conclusion, there was a significant
positive correlation between increased
oxidative stress and elevated plasma lev-
els of AM in hypertensive patients with
type 2 diabetes. Enhanced oxidative stress
may regulate the plasma levels of AM in
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D iabetic eye disease is the leadingcause of new cases of blindness inmany developed countries, for
which macular edema and proliferative
retinopathy are major causes of loss of vi-
sion (1). Genetic studies have previously
suggested that diabetic retinopathy is
partly determined by genetic factors (2).
Angiotensin II, produced locally within
the retina, has potent hemodynamic and
growth-promoting effects and stimulates
ocular neovascularization (3,4). The pres-
ence of retinopathy is associated with an
activated renin-angiotensin system (RAS)
(5), and inhibition of the RAS signifi-
cantly reduced the progression of reti-
nopathy in nonhypertensive patients with
type 1 diabetes (6). The ACE gene inser-
tion/deletion (I/D) polymorphism has
been reported to be associated with reti-
nopathy in type 1 diabetic subjects, but
the findings are heterogeneous (7,8).
Only limited data are available describing
the angiotensinogen (AGT) M235T and
the angiotensin II type 1 receptor (AT1R)
A1166C polymorphisms and retinopathy
(9,10).
In this study, we examined the asso-
ciations between these three polymor-
phisms and diabetic retinopathy in 827
Chinese type 2 diabetic patients (based on
1985 World Health Organization crite-
ria). All subjects gave written informed
consent and were of Han Chinese origin.
They were examined by the physicians or
ophthalmologists through dilated pupils.
Retinopathy was considered to be present
if there was one or more areas of hemor-
rhages, microaneurysms, cotton wool
spots, and/or laser coagulation scars re-
lated to diabetic retinopathy or history of
vitrectomy (11). The RAS genotype and
allele frequencies were identified using
PCR/restriction fragment–length poly-
morphism protocols (12) in 326 patients
with retinopathy and 501 diabetic pa-
tients without retinopathy who were
matched for age (59.8  11.4 vs. 60.4 
Letters
DIABETES CARE, VOLUME 26, NUMBER 5, MAY 2003 1643
9.3 years), sex (44.2 female vs. 39.3%
male), disease duration (6.3 [range 5.6–
7.0] vs. 6.0 years [5.6–6.3]), and age of
onset of diabetes (53.2  9.7 vs. 51.9 
12.4 years). Of those with retinopathy,
66.6% had nonproliferative, 8.3% pre-
proliferative, and 8.9% proliferative dis-
ease and 16.2% had advanced eye disease.
Of the patients, 30.1% with retinopathy
had received laser therapy in at least one
eye, with 18.7, 29.2, 53.8, and 69.4% be-
ing treated in the groups with increasing
severity of retinopathy.
The allele frequencies were 32.7 and
32.1% for the ACE D allele, 16.1 and
13.8% for the AGT M allele, and 4.6 and
3.4% for the AT1R C allele in those with-
out and with retinopathy, respectively.
The genotype distributions for these gene
polymorphisms are described in Table 1.
No differences were identified in the ge-
notype or allele frequencies between the
groups either for the dichotomous classi-
fication of retinopathy or when the sever-
ity of the retinopathy was graded.
The ACE D allele has been associated
with increasing ACE levels (12). Subjects
with the angiotensinogen M235T poly-
morphism TT genotype have increased
serum AGT levels, while the AT1R 1166C
allele is associated with enhanced respon-
siveness to angiotensin II (13). The ACE
DD genotype was found to be associated
with the presence of proliferative retinop-
athy in a relatively small case-control
study of type 1 diabetic subjects (7). In
the current study, the analysis compar-
ing age-, sex-, and diabetes duration–
matched subjects found no evidence of
associations between the distribution of
genotypes or alleles of these RAS gene
polymorphisms and retinopathy. Our
data support the majority of the literature
regarding the ACE I/D gene polymor-
phism, which has reported no significant
association with retinopathy in diabetic
patients (7,8).
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S tudies have shown a 4% prevalenceof celiac disease in type 1 diabeticpatients. Few data, however, are
available on the prevalence of type 1 dia-
betes–related antibodies in patients with
celiac disease, with studies being limited
by the recruitment of low numbers of
children only (1,2). We have assessed
prevalence of type 1 diabetes–related au-
toantibodies (islet cell antibody [ICA],
GAD antibody [GADA], and antibodies to
the protein tyrosine phosphatase–related
IA-2 [anti-IA2]) in a cohort of 378 nondi-
abetic adults with celiac disease (89 un-
treated and 289 treated with a gluten-free
diet), aged 33.9  14.7 years (range
15.7–81.3), who were cared for at our
outpatient clinic. Known duration of glu-
Table 1—Genotype distributions for the ACE I/D, AGT M235T, and angiotensin type 1









n 501 326 225 101
ACE DD/ID/II 11.6/42.3/46.1 12.3/39.6/48.2 11.4/37.8/50.7 14.9/42.6/42.6
AGT TT/MT/MM 69.7/28.5/1.7 74.2/24.0/1.8 75.0/23.8/1.2 77.0/20.7/2.3
AT1R AC/AA 9.2/90.8 6.6/93.4 8.1/91.9 6.5/93.5
No significant differences were identified between the groups.
Letters
1644 DIABETES CARE, VOLUME 26, NUMBER 5, MAY 2003
ten withdrawal was 5 years in 146
(48.2%), 5–9 years in 54 (17.8%), and
9 years in 103 (34.0%) patients. GADAs
were measured by a radioligand assay us-
ing human recombinant GAD 65 as anti-
gen (Medipan Diagnostica, Selchow,
Germany), ICAs by indirect immunoflu-
orescence on frozen sections of human
blood group 0 pancreas with fluorescein
isothiocyanate-conjugated rabbit anti-
bodies, and anti-IA2 by a radioligand as-
say using highly purified human
recombinant IA2 labeled with 125I (Medi-
pan Diagnostica).
Of 289 treated nondiabetic patients,
26 had type 1 diabetes–related autoanti-
bodies, giving a prevalence of 9.0% (95%
CI 6.7–12.3). All of them, however,
showed no more than one marker positiv-
ity (2.8% ICA, 3.1% GADA, 3.1% anti-
IA2). Untreated celiac patients had a
similar prevalence (10.0%, P  0.75). In
linear regression analysis, levels of anti-
IA2 were linearly associated with dura-
tion of celiac disease (	  0.002, P 
0.05). In logistic regression analysis, du-
ration of gluten withdrawal was indepen-
dently associated with a prevalence of
type 1 diabetes–related autoantibodies.
With respect to duration 5 years, a four-
fold increased risk in patients with dura-
tion 9 years was found (95% CI 1.51–
10.6), even after adjustment for age, sex,
presence of other autoimmune diseases,
and compliance to diet. In a mean fol-
low-up time of 3.0  1.3 years (range
1.3–6.5), however, no incident case of
type 1 diabetes was diagnosed in either
patients with (79.0 person-years) or with-
out (782.7 person-years) autoimmune
markers.
In conclusion, this study shows that
prevalence of type 1 diabetes–related au-
toantibodies in adults with celiac disease
is high (9.0%), even after dietary gluten
withdrawal, and that it increases over
time but is associated with low risk of pro-
gression to diabetes. These findings are
consistent with a role of common genetic
susceptibility of both diseases, such as
factors involved in intestinal permeabil-
ity. Case-control studies show association
between various dietary factors and risk of
type 1 diabetes (3). Dietary gluten could
act as modifier rather than determinant of
type 1 diabetes, facilitating the progres-
sion of other dietary factors to the lamina
propria, where they activate the autoim-
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The effectiveness of interventions thatreduce hyperglycemia in patientswith diabetes (1,2) is limited by the
tendency for glycemic relapse after the in-
tervention ends. We sought to character-
ize the occurrence of glycemic relapse
after initial improvement and to describe
predictors of relapse.
Glycemic relapse was evaluated in
265 consecutive patients with type 2 dia-
betes who participated in a 3-month in-
tensive outpatient intervention and were
followed at least 1 year after completion of
the intervention. Details of the interven-
tion have been previously described (3).
All had HbA1c 8% before the interven-
tion and had achieved marginal glycemic
control (nadir HbA1c 8%) after the in-
tervention. Glycemic relapse was defined
as a subsequent HbA1c 8% and an ab-
solute increase of at least 1% above the
postintervention nadir HbA1c. All data
were analyzed using SAS 8.12 (SAS Insti-
tute, Cary, NC).
The mean  SD age was 56  13.4
years; 54% were women; 71% were Cau-
casian; and 27% were African American.
The mean duration of diabetes was 6.4 
8.4 years. Mean BMI was 32.2  8.6 kg/
m2. The mean HbA1c before interven-
tion was 10.1  1.7%. The mean HbA1c
nadir after intervention was 6.8  0.7%.
Twenty-five percent were receiving insu-
lin therapy before the intervention, and
an additional 25% initiated insulin during
the program.
The cumulative incidence of relapse
at 1 year was 25%. The initiation of insu-
lin therapy during the intervention was
the only identifiable independent predic-
tor of relapse (hazard ratio 1.96, 95% CI
1.02–3.74). Female sex, African-
American race, duration of diabetes, lack
of weight loss during the intervention pe-
riod, and the levels of HbA1c before the
intervention and at nadir after the inter-
vention increased the risk of relapse in
univariate analysis, but these associations
were not statistically significant in multi-
variate modeling. For those patients who
relapsed, the median time to relapse was 9
months. Kaplan-Meier plots estimated
that 50% of the population would relapse
by 30.3 months.
Twenty-five percent of type 2 patients
who attained satisfactory glycemic con-
trol after an intensive outpatient interven-
tion relapsed within a year. Patients who
initiated insulin therapy during the inter-
vention had an almost double risk of re-
lapse. Future studies should characterize
social and behavioral variables as well as
the frequency and type of insulin in order
to better understand the relapse process.
In the interim, this high-risk subgroup
should receive priority for continuation of
intensive care or other relapse preventive
measures.
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Twin pregnancies have been associ-ated with adverse obstetric and neo-natal outcomes. The incidence of
respiratory distress syndrome in the new-
borns of multiple pregnancy patients is
probably related to the higher incidence
of preterm delivery. However, the com-
plications of twin pregnancies are not
limited to infants; miscarriages, pre-
eclampsia, anemia, placenta previa, poly-
hydramnios, and premature rupture of
membranes are more frequent than in sin-
gleton pregnancy. There have been a few
reports that test the hypothesis that mul-
tiple gestation could also be a risk factor
for gestational diabetes (1– 6). These
studies utilized various criteria for diag-
nosing gestational diabetes (World
Health Organization [1], National Diabe-
tes Data Group [2–4], and Carpenter and
Coustan [7]) and did not report the per-
centage of the positive glucose challenge
test for each group.
To determine the prevalence of gesta-
tional diabetes (using the Carpenter and
Coustan criteria) in singleton and twin
pregnancies in a cohort population of
women who had had screening for ges-
tational diabetes from January 1990 to
January 2000, we started a retrospec-
tive study on 2,554 pregnant women
screened for gestational diabetes in the
Department of Obstetrics and Gynecol-
ogy of our University Hospital. Of these,
70 were multiple pregnancies. A 50-g oral
glucose challenge test was performed be-
tween 24 and 28 weeks’ gestation, and a
1-h value 135 mg/dl was considered
positive and followed by a 100-g oral glu-
cose tolerance test. The results were inter-
preted according to the Carpenter and
Coustan threshold values (95, 180, 155,
and 140 mg/dl) at fasting and after 1, 2,
and 3 h, respectively. If two thresholds
were met or exceeded, then the diagnosis
of gestational diabetes was made. Age, fa-
milial or personal anamnestic factors, par-
ity, and BMI at first visit, all considered
risk factors for GDM, were recorded in
our database. A positive glucose challenge
test occurred in 520 of 2,554 pregnant
women (20.3%). The test was positive in
22 of 70 (31.4%) multiple pregnancies
and 498 of 2,484 (20.0%) singleton preg-
nancies (P  0.029). The rates of GDM
were 80 of 2,484 (3.6%) in singleton and
4 of 70 (5.7%) in twin pregnancies (P 
0.416). No statistically significant differ-
ences exist for the maternal risk factors for
GDM between the two groups.
The decreased insulin sensitivity in
pregnancy may be modified by several
factors, such as diet, BMI, maternal age,
and the placental mass, all of which may
play a role affecting 	-cell function and
sensitivity to insulin. It has been sug-
gested that in multiple pregnancies with
two placentas or one that is larger, the
incidence of gestational diabetes may be
increased (3,4,6). Our data show that in
our Sicilian population, twin pregnancy
cannot be considered a proven risk factor
for gestational diabetes. In fact, the differ-
ences (3.6 vs. 5.7%) are not statistically
different. Our data showed that one-third
of twin pregnancies (22 of 70, 31.4%)
manifest a positive glucose challenge test,
as compared with 20% of singleton preg-
nancies (498 of 2,484). It seems possible
that with a larger sample size, the differ-
ence in incidence of gestational diabetes
might have been statistically significant,
although of questionable clinical signifi-
cance. Another hypothesis could be that
the greater relative elevation of anti-
insulin placental hormone levels in a twin
gestation may precipitate a mild degree of
glucose intolerance in a woman who
would have been normal with a singleton
pregnancy. If this were the case, the im-
pact of such a mild degree of glucose in-
tolerance remains undetermined.
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I t has been postulated that type 2 dia-betes is a manifestation of the inflam-matory host response (1). Increased
inflammatory activity is believed to play
a critical role in development of athero-
genesis and to predispose established
atherosclerotic plaques to rupture (2). In-
terleukin (IL)-8 is a potent chemoattractant
(chemokine) and induces recruitment of
neutrophils and T-cells into the subendo-
thelial space, as well as adhesion of mono-
cytes to endothelium (3). IL-18 is a potent
proinflammatory cytokine reported to
play a role in plaque destabilization and to
predict cardiovascular death in patients
with coronary artery disease (4). Adi-
ponectin is an adipocyte-derived plasma
protein (adipokine) that accumulates in
the injured artery and has potential anti-
atherogenic properties; male patients
with hypoadiponectinemia present a two-
fold increase in coronary artery disease
prevalence (5).
We studied 30 patients (age 42  4
years, BMI 26.9  1.2 kg/m2, and HbA1c
7.2  0.6% [mean  SD]) with newly
diagnosed type 2 diabetes (within 6
months of diagnosis) without hyperten-
sion or evidence of vascular complica-
tions treated only by diet. Thirty healthy
subjects, matched for age, sex, and body
weight, served as the control group. None
of the subjects (diabetic and nondiabetic)
were taking any drugs. Serum samples for
IL-8, IL-18, and adiponectin were stored
at 80°C and measured in duplicate us-
ing enzyme-linked immunosorbent kits.
All samples for a given patient were ana-
lyzed in the same series.
Circulating levels of IL-8 and -18 con-
centrations were higher in diabetic pa-
tients (13.7  2.8 and 205  39 pg/ml,
respectively) than in control subjects
(8.7  1.9 and 120  25 pg/ml, P 
0.05–0.001), while circulating adiponec-
tin levels were lower (4.9  1.2 vs. 7.1 
1.9 g/ml, P  0.01). There was a signif-
icant correlation between fasting glucose
and IL-8 levels in diabetic patients (r 
0.31, P  0.05); adiponectin concentra-
tions were negatively correlated with fast-
ing insulin levels (r  0.43, P  0.01).
Our study shows that circulating IL-8
concentrations are significantly higher
and adiponectin levels are significantly
lower in type 2 diabetic patients than
matched control subjects. Previous stud-
ies reported similar findings (6,7). To our
knowledge, this is the first demonstration
that circulating IL-18 concentrations are
increased in type 2 diabetic patients, as
compared with age-, sex-, and body
weight–matched nondiabetic subjects. In
a prospective study of 1,229 subjects, in-
cluding one-sixth of diabetic patients,
with documented coronary artery dis-
ease, serum IL-18 concentration was
identified as a strong independent predic-
tor of future cardiovascular events (5).
The correlation we found between IL-18
and glucose levels in diabetic patients and
the evidence that acute hyperglycemia
may increase circulating IL-18 levels in
healthy subjects and IGT patients (8) sug-
gest a role for this cytokine in plaque de-
stabilization associated with stress
hyperglycemia (9).
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CD36 is an 88-kDa membranous pro-tein with multiple relevant functionthat is widely expressed in human
tissues (1). Because we and others (2)
found human genetic deficiency of this
molecule, we have elucidated the molec-
ular bases and pathophysiology. We have
reported that the human deficiency may
be associated with insulin resistance (3)
and abnormal dynamics of long-chain
fatty acid (LCFA) (4). The aim of the
present study was to further characterize
lipid and lipoprotein metabolism in the
human genetic CD36 deficiency, espe-
cially focusing on postprandial responses.
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Seven Japanese patients with type I
CD36 deficiency (cases 1–7) were sub-
jected. They were divided into the follow-
ing two groups: group A, two younger
patients we have recently identified (cases
1 and 2); and group B, patients 50 years
of age (cases 3–7, reported in our previ-
ous paper [3]). For the analysis of each
group, aged-matched healthy and nono-
bese volunteers were subjected as control
subjects (Table 1). First, we confirmed
that insulin resistance was also present in
the two younger patients (group A).
At the fasting state, “midbands,”
which imply the accumulation of rem-
nant lipoproteins, were observed in group
B but not in group A. Preparative ultra-
centrifugation confirmed an increase in
intermediate-density lipoprotein choles-
terol in the all of the CD36-deficient sub-
jects in group B compared with the
control subjects. The oral fat loading test
demonstrated that the patients in group B
presented postprandial hyperlipidemia
with the accumulation of small intestine–
derived lipids. Whereas the patients in
group A did not show apparent abnor-
malities, though they did have insulin
resistance.
The present study indicated that this
monogenic disorder with the abnormal
metabolism in LCFA and insulin resis-
tance may cause the phenotypic expres-
sion of hyperlipidemia at both fasting and
postprandial states. These data also sug-
gest that the clinical manifestation is af-
fected by the acquired factors, such as
aging and dietary contents. We believe
that human genetic CD36 deficiency may
be a monogenic form of “metabolic syn-
drome.” Further studies to elucidate mo-
lecular mechanism for the phenotypic
expression in CD36-deficient states are
under way in our laboratories.
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With <20 Years of
Evolution
Obesity and reduced levels of physi-cal activity are directly associatedwith the insulin resistance that
characterizes type 2 diabetes (1,2). Phys-
ical activity is one of the cornerstones of
type 2 diabetes management (3). Few
Table 1—Lipid and lipoprotein abnormalities at fasting and postprandial states in human genetic CD36 deficiency
Group A Group B
Case 1 Case 2 Control (n  4) Case 3 Case 4 Case 5 Case 6 Case 7 Control (n  8)
Age (years)/sex (M/F) 34/M 32/M 33  2 (4M) 58/M 65/F 54/F 54/F 54/M 55  10 (3M/5F)
BMI (kg/m2) 22.9 32.0 22.4  1.0 26.2 22.2 32.8 17.3 24.9 22.7  2.3
WBGU (mg  kg1  min1)* 7.8 2.8 9.1  0.5 2.67† 7.09† 5.49† 4.85† 5.29† 8.6  0.5†
Fasting state
Total cholesterol (mmol/l) 4.20 5.01 4.78  0.38 5.81 6.18 5.97 5.45 5.84 5.10  0.69
Triglyceride (mmol/l) 0.78 1.23 1.00  0.17 2.73 1.43 1.77 1.28 3.41 1.20  0.38
Midband in PAG disc
electrophoresis‡
      
IDL cholelsterol (mmol/l)§ ND ND 0.48 0.38 0.29 0.34 0.22 0.11  0.03
Postprandial state
AUC-TG (mmol/l 6 h) 5.3 8.8 8.8  0.7 20.6 13.4 14.0 14.0 26.8 10.0  2.9
AUC-Apo B48 (AU/ml 6 h)** 223 268 329  107 866 671 941 551 541 360  120
Data are means  SD unless otherwise indicated. apo, apolipoprotein; AUC, area under the curve; PAG, polyacrylamide gel; WBGU, mean whole-body glucose
uptake. *Insulin resistance was determined by euglycemic clamp technique (ref. 3); †part of data from cases 3–7 were described previously (Ref. 3); ‡lipoproteins
were analyzed by PAG electrophotesis. §IDL was separated by preparative ultracentrifugation (1.019  d  1.063 g/ml); postprandial hyperlipidemia was analyzed
by the oral fat loading test with fat cream containing 30 g fat/m2 body surface area; TG and apo B48 levels were measured at 0, 2, 4, and 6 h after loading, and AUCs
were calculated; **serum apo B48 levels were measured by the enzyme-linked immunosorbent assay we have developed.
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large studies have assessed the impact of
intensity and quality of exercise on meta-
bolic control in these patients, and the
influence of age on the metabolic re-
sponse to physical activity is still contro-
versial (4). We conducted the Intervention
on Key Cardiovascular Risk Factors in
Type 2 Diabetes National Study (KAREN),
a country-based case-control study nested
in a survey of 1,485 consecutive type 2
diabetic patients treated by 208 endocri-
nologists across Spain to assess the impact
of physical activity on metabolic control.
Patient risk factors, history characteris-
tics, medication and diet compliance, gly-
cemia, fasting HbA1c, and lipids were
determined.
Patient characteristics are presented
in Table 1 by quartile of physical activity.
After adjustment for age, sex, triglycer-
ides, BMI, and diet compliance, patients
in the lowest quartile of physical activity
had an OR of 1.52 and a 95% CI of 1.11–
2.08 for having an HbA1c 7.5%. The
ORs for patients 65 years of age and in
the lowest quartile of physical activity
were 1.55 (95% CI 1.04–2.31) compared
with the fourth, 1.64 (1.09–2.47) with
the third, and 1.84 (1.22–2.75) with the
second quartile. Patients 65 years of age
and in the lowest quartile of physical ac-
tivity had a similar adjusted risk com-
pared with the rest of quartiles (OR 1.14,
95% CI 0.70–1.85; 1.38, 0.84–2.26, and
0.87, 0.53–1.43, respectively). A signifi-
cant reduction of 0.2% (95% CI 0.36 to
0.04) in HbA1c was observed for pa-
tients expending 50 kcal/day versus the
first quartile; the reduction for patients
65 years of age was 0.27% (0.49 to
–0.06), but for patients 65 there was no
significant difference.
These results suggest that physical ac-
tivity produces better glycemic control
and improved cardiovascular risk profile
in diabetic patients, particularly in those
65 years of age.
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Appendix
The KAREN Investigators comprise 208
Spanish endocrinologists who work in
primary outpatient diabetes clinics of the
National Health Service.
The KAREN investigators are as fol-
lows: Abellán T, Acha FJ, Acosta D, Agui-
lar M, Aguillo E, Albero R, Alcaraz M,
Alvarez JA, Alvarez P, Alvarez J, Andia
VM, Aranda S, Arranz A, Arribas LD, Ar-
teaga R, Asensio C, Ayala C, Ballester E,
Barril R, Becerra A, Blanco B, Blay V, Botas
P, Brito MA, Bruscas M, Bueno J, Burgo R,
Cabezas J, Calderón D, Calero M, Calvo F,
Cáncer E, Carrasco R, Casal F, Castaño G,
Castro JC, Cepero D, Cervello G, Chena
JA, Conget I, Corrales JJ, Costilla E, Coves
MJ, Darı́as R, de la Cuesta C, de Pablos P,
Dı́az C, Diez A, Domı́nguez JR, Duran S,
Duran M, Elviro R, Enrı́quez L, Escalada
FJ, Escobar L, Esmatges E, Espiga J, Es-
topiñan V, Ezquerra R, Famades A, Fer-
nández JI, Fernández M, Fernández JM,
Fernández F, Fernández T, Fernández JA,
Fernández J, Flández B, Flaquert P, Fraile
AL, Fraile J, Freijanes J, Galvez A, Garcı́a
Table 1—Demographic, comorbidity, lifestyle, biochemical, and somatometric characteristics by physical activity levels (quartiles) of type 2
diabetic patients who participated in the KAREN study
51 kcal/day 51–148 kcal/day 149–264 kcal/day 264 kcal/day P
n 368 373 375 369
Age (years) 62  10 61  10 61  9 61  10 NS
Women (%) 49.6 45.3 54.4 69.6 0.001
Time with diabetes (years) 10.3  6.4 9.9  6.3 10.1  6.4 10.3  6.2 NS
Hypertension (%) 51.8 58.3 50.7 46.3 0.017
Current smokers (%)* 19.4 18.9 19.0 16.0 NS
Systolic BP (mmHg) 140  17 139  17 139  16 139  19 NS
Diastolic BP (mmHg) 80  10 79  9 79  10 78  11 NS
BMI (kg/m2) 28.8  3.4 28.5  3.5 28.1  3.3 28.3  3.3 0.035
Coronary heart disease (%)† 17.9 14.4 18.0 14.0 NS
Cerebrovascular disease (%)‡ 8.5 6.4 6.6 5.1 NS
Glycemia (mg/dl) 9.5  3.2 9.1  2.9 9.1  3.0 8.8  2.7 0.001
HbA1c (%)* 7.9  1.6 7.6  1.4 7.6  1.4 7.4  1.0 0.001
Total cholesterol (mmol/l) 5.3  1.0 5.4  1.0 5.2  1.0 5.1  1.0 0.001
HDL cholesterol (mmol/l) 1.2  0.3 1.3  0.3 1.2  0.3 1.3  0.4 0.014
LDL cholesterol (mmol/l) 3.4  0.9 3.4  0.9 3.2  34.7 3.3  0.9 NS
Triglycerides (mmol/l) 1.9  1.8 1.7  0.9 1.7  1.1 1.5  0.9 0.001
Creatinine (mol/l) 91.9  31.8 85.7  24.7 86.6  26.5 88.4  19.4 0.035
Good diet compliance (%) 37.1 35.1 49.2 52.2 0.001
Daily alcohol consumption (g) 12.9  12.8 12.5  12.3 12.8  13.3 12.5  12.3 NS
Data are means  SD and %. *Smokers of at least one cigarette per day in average; †myocardial infarction or angina; ‡transient ischemic attack or stroke.
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JA, Garcı́a A, Garcı́a C, Garcı́a G, Garcı́a I,
Garcı́a J, Garcı́a M, Garcia-Hierro V, Gar-
gallo MA, Gentil AC, Gil A, Gilsanz A,
Giménez G, Gippini A, Girbés AJ, Goday
A, Godoy DV, Goena M, Goicolea I, Gó-
mez F, González A, González JM, Gonzá-
lez O, Goñi F, Guerrero E, Hernández C,
Hernández A, Hernández JA, Hernández
C, Hernández A, Hernández C, Iglesias P,
Ikobalceta P, Illan F, Iñigo P, Iriarte A,
Irigoyen L, Jaunsolo MA, Lain T, Levy I,
Llorente I, López AJ, López de la Torre M,
López-Guzman A, Losada F, Luna R, Ma-
canas G, Macia C, Maldonado JA, Mangas
MA, Manzanares JM, Maravall FJ, Marco
A, Marco AL, Marin M, Martı́n T, Martı́n
A, Martı́nez MP, Martı́nez FJ, Martı́nez
MA, Matia P, Mato JA, Megia A, Menén-
dez E, Meoro A, Merino JF, Mesa J,
Mezquita P, Micalo T, Miralles JM, Molina
MJ, Monereo S, Morales MJ, Moreno A,
Moreno C, Mories T, Muñoz L, Muñoz M,
Muñoz A, Muros T, Nubiola A, Oleaga A,
Oliván B, Palacios N, Palomares R, Pazos
F, Pena E, Peñafiel FJ, Pereyra F, Pérez A,
Pesquera C, Picon MJ, Piedrola G, Pinedo
R, Piniés J, Pizarro E, Prieto J, Puig M,
Puigdevall V, Pumar A, Recas I, Recio JM,
Reverter J, Ricart W, Rius F, Rivas M,
Rosell R, Rubio JA, Ruiz JM, Sagarra E,
Sales J, Salinas I, Sánchez C, Sánchez JC,
Santiago P, Santiago L, Sastre J, Segura P,
Simo R, Simón I, Solache I, Soriano J, Soto
A, Suarez-Lledo E, Surruca L, Tebar FJ,
Tenes T, Todolı́ J, Tofe S, Tolosa M, Tor-
ras R, Torres A, Vadillo V, Velasco JL,
Vences LF, Vendrell JJ, Vicente A, Vidal JI,
Villa M, Villar A, Zurro J.
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Education and
Mortality in Type 2
Diabetes
A dults with diabetes tend to havehigher age-adjusted mortality rates(1,2). Evidence from Britain (3)
suggests that mortality in diabetic adults
is inversely related to socioeconomic sta-
tus. The importance of self-care and
blood glucose control in adults with dia-
betes suggests that education may be an
important factor in long-term health out-
comes, a hypothesis that is also consistent
with evidence in the health economics lit-
erature that education increases the effi-
ciency of investment in health (4,5). The
specific hypothesis tested here is that
mortality in adults with diabetes is in-
versely related to education.
The data are taken from the National
Health Interview Survey (NHIS) of 1989,
including its diabetes supplement, with
mortality status taken from the NHIS
Multiple Cause of Death Public Use Data
File, including deaths from 1989 to 1995.
The statistical analysis is applied to those
adults who self-reported that they had
been diagnosed with diabetes, excluding
those with apparent type 1 diabetes (age
of onset 30 years, with insulin depen-
dence, and a BMI 27.2 kg/m2 for men
and 26.9 for women). The resulting
sample includes 2,387 adults with type 2
diabetes having an average age of 61.8
years.
Logistic regression analysis is used to
explore the relation between mortality
and educational attainment, family in-
come (greater than or less than $20,000
per year in 1989), age, sex, marital status,
race, and duration of diabetes. The statis-
tical analysis is carried out with the svy-
logit procedure in STATA software,
version 7 (STATA, College Station, TX),
using the NHIS sampling weights.
The primary finding is that mortality
is inversely related to education for dia-
betic adults (OR [95% CI] 0.61 [0.40–
0.93] for college graduation or higher and
0.78 [0.61–0.99] for high school gradu-
ation or higher). Mortality is not signifi-
cantly related to family income, marital
status, or race, but age, male sex, and du-
ration of diabetes have the expected pos-
itive and statistically significant associations
with mortality. The finding that educa-
tion reduces the mortality risk of diabetic
adults is consistent with the predictions
from health investment theory that edu-
cation increases the efficiency of health
investment. Education may also be a fac-
tor in the relatively poor health status and
outcomes of adults with diabetes (6).
Acknowledgments— The author thanks
Philip Jacobs for comments, Glenn Harrison
for generous help with the data, and Paula
Veiga for expert research assistance. Any re-
maining errors are mine.
RONALD P. WILDER, PHD
From the Department of Economics, Moore School
of Business, University of South Carolina, Colum-
bia, South Carolina.
Address correspondence to Ronald P. Wilder,
PhD, Department of Economics, Moore School of
Business, University of South Carolina, Columbia,
SC 29208. E-mail: ronwildr@darla.badm.sc.edu.
© 2003 by the American Diabetes Association.
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
References
1. Geiss LS, Herman WH, Smith PJ: Mortal-
ity in non-insulin dependent diabetes. In
Diabetes in America. 2nd ed. National
Diabetes Data Group, National Institutes
of Health, National Institute of Diabetes
and Digestive and Kidney Diseases, 1995
(NIH Publ. no. 95-1468)
2. Gu K, Cowie CC, Harris MI: Mortality in
adults with and without diabetes in a na-
tional cohort of the U.S. population,
1971–1993. Diabetes Care 21:1138–
1145, 1998
3. Roper NA, Bilous RW, Kelly WF, Unwin
NC, Connolly VM: Excess mortality in a
population with diabetes and the impact
of material deprivation: longitudinal,
population based study. BMJ 322:1389–
1393, 2001
4. Grossman M, Kaestner R: Effects of edu-
cation on health. In The Social Benefits of
Education. Behrman J, Stacey N, Eds. Ann
Arbor, MI, University of Michigan Press,
1997
5. Kahn ME: Education’s role in explaining
diabetic health investment differentials.
Econ Educ Rev 17:257–266, 1998
6. Harris MI: Health care and health status
and outcomes for patients with type 2 di-





One-third of all individuals with hy-perglycemia admitted to an urbangeneral hospital do not have a pre-
vious diagnosis of diabetes; in these pa-
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tients, hyperglycemia is a risk factor for
adverse outcomes during acute illness (1).
For example, in patients presenting with
acute myocardial infarction, glucose val-
ues in excess of 6.1–8.0 mmol/l were as-
sociated with a threefold increase in
mortality and a higher risk of heart failure
(2). Control of hyperglycemia with inten-
sive insulin therapy during acute illness
results in marked improvements of clini-
cal outcomes (3).
Dandona et al. (4) put forward a
working hypothesis linking in a feedback
loop of glucose (and possibly other nutri-
ents), insulin, and inflammation. Accord-
ing to this paradigm, hyperglycemia has a
proinflammatory action that is normally
restrained by the anti-inflammatory effect
of insulin secreted in response to that
stimulus. A likely corollary of this para-
digm is that the proinflammatory effects
of acute (stress) hyperglycemia may be
implicated in the poor prognosis of hos-
pitalized patients with or without diabe-
tes (particularly death, disability after
acute cardiovascular events, and infec-
tions). We have demonstrated that circu-
lating levels of some proinflammatory
cytokines are regulated by glucose levels
in humans (5). Acute hyperglycemia
(15 mmol/l) induced by glucose clamp-
ing in normal subjects and lasting 5 h
determines a significant increase of inter-
leukin (IL)-6, IL-18, and tumor necrosis
factor-
 (TNF-
) circulating levels. These
effects were more sustained in patients
with impaired glucose tolerance, as well
as following consecutive pulses of intra-
venous glucose, and were annulled by
glutathione, implicating an oxidative
mechanism. Interestingly enough, these
cytokines have been implicated in insulin
resistance (TNF-
 and IL-6), atheroscle-
rotic plaque destabilization (IL-18), and
future cardiovascular events (IL-6, IL-18,
and TNF-
). So, an increased oxidative
stress may be a likely mechanism linking
stress hyperglycemia to cardiovascular
events via an increased cytokine production.
Free fatty acids (FFAs) also induce
proinflammatory changes. During illness,
stress increases the concentration of
counterregulatory hormones (mainly glu-
cagon, an epinephrine). Given this back-
ground, it is plausible that in the presence
of high concentrations of both glucose
and FFA, inflammation is more promi-
nent. We tested this hypothesis by giving
type 2 diabetic patients two different
meals: a high-carbohydrate meal (high
glucose levels) and a high-fat meal (high
glucose plus high FFA levels). In the latter
condition, the serum concentrations of
cytokines (TNF-
 and IL-6) and adhesion
molecules (intracellular adhesion mole-
cule-1 and vascular cell adhesion mole-
cule-1) were at the highest level (6).
In conclusion, high circulating con-
centrations of glucose and FFAs may ex-
plain, at least in part, the oxidative and
inflammatory derangements during acute
illness; insulin may exert its anti-inflam-
matory action by ameliorating glucose
and lipid parameters. However, any addi-
tional anti-inflammatory effect insulin
may have of its own is welcome. The im-
portance is to recognize that treatment of
even trivial hyperglycemia during acute
illness is fundamental to improve sur-
vival. Because insulin is the best choice to
normalize glucose control during stress,
accepting the premise will inevitably
bring increased insulin use in intensive
care units.
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N egative emotions such as anxiety,fear, and sorrow are known to befactors that elevate the blood glu-
cose level (1). Conversely, positive emo-
tions such as laughter have been reported
to modify the levels of neuroendocrine
factors involved in negative emotions
(2,3) and to modulate immune function
(3,4). However, there have been no stud-
ies on the effects of laughter on blood glu-
cose level. The purpose of this study was
to clarify changes in the blood glucose
level after laughing episodes in patients
with diabetes.
A 2-day experiment was performed in
19 patients with type 2 diabetes not re-
ceiving insulin therapy (16 men and 3
women, age 63.4  1.3 years, BMI
23.5  0.7 kg/m2, HbA1c, 7.2  0.1%
[means  SE]) and 5 healthy subjects
(2 men and 3 women, age 53.6  3.5
years, BMI 24.3  1.6 kg/m2, HbA1c
4.8  0.1% [means  SE]). On both ex-
perimental days, they consumed the same
500-kcal meal (79.9 g carbohydrate,
21.0 g protein, 7.8 g fat, and 1.0 g fiber).
On the first day, they attended a monot-
onous lecture (40 min) without humor-
ous content. On the second day, as part
of an audience of 1,000 people attend-
ing MANZAI (a Japanese cross-talk com-
edy) (40 min) in a civic hall, the subjects
laughed. Blood glucose was measured
from the fingertip by enzyme colorimet-
ric assay using a blood glucose self-
measurement apparatus. The subjects
estimated their laughter level on a scale of
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0–5, and most of them considered that
they laughed well (level 4 or 5). Self-
monitoring of blood glucose was per-
formed before food intake (fasting blood
glucose [FBG]) and 2 h after the meal was
started (2-h postprandial blood glucose
[PPBG]).
The results are presented as means 
SE. In the patients, the mean 2-h PPBG
was 6.8  0.7 mmol/l higher than the
FBG after the lecture and 4.3  0.8
mmol/l higher after the comedy show.
The difference in the mean increase be-
tween the lecture and comedy show was
2.5  0.7 mmol/l (P  0.005). In the
healthy subjects, the mean increases were
2.0  0.7 and 1.2  0.4 mmol/l after the
lecture and comedy show, respectively,
and the difference was 0.8  0.5 mmol/l
(P  0.138).
These results suggest a significant
suppression of the increase in 2-h PPBG
by comedy show in patients with diabe-
tes, suggesting that laughter ameliorates
the postprandial glucose excursion in the
presence of insufficient insulin action.
This favorable effect of laughter may in-
clude the acceleration of glucose utiliza-
tion by the muscle motion during the
comedy show. However, it is possible that
positive emotions such as laughter acted
on the neuroendocrine system and sup-
pressed the elevation of blood glucose
level.
In conclusion, the present study elu-
cidates the inhibitory effect of laughter on
the increase in PPBG and suggests the im-
portance of daily opportunities for laugh-
ter in patients with diabetes.
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CIII in Men on Either
Statin or Fibrate
Therapy
H igh triglycerides and low HDL cho-lesterol are frequently associatedwith insulin resistance. Statins are
potent hypocholesterolemic drugs, while
fibrates are better at reducing triglycer-
ides and enhancing HDL. However, little
is known of their effects on other param-
eters potentially associated with insulin
resistance, such as -glutamyl transferase
(GGT) (1) and apolipoprotein CIII (2).
In this cross-sectional study, we have
analyzed the biochemical profiles of 500
men from Southwestern France as a func-
tion of their hypolipidemic therapy.
Comparison between untreated (n 
361) and fibrate (n  50)- and statin (n 
89)-treated subjects revealed no differ-
ence in their levels of total, LDL, and HDL
cholesterol, apo B, apo AI, and apo E, after
adjustment for age, BMI, alcohol intake,
smoking, and physical activity. This sug-
gests that both therapies are equally effec-
tive at normalizing classic lipid variables.
By contrast, apo CIII was higher in the
statin group (34.3  13.9 mg/l) than in
both the fibrate (26.7  10.3, P  0.01)
and nontreated (28.7  10.9 mg/l, P 
0.001) groups after adjustment for con-
founders, including triglycerides. Similar
differences were found for Lp B:CIII, a
marker measuring apo CIII associated
with apo B. These observations might in-
dicate an additional beneficial effect of fi-
brates, considering that Lp B:CIII has
been described as an independent predic-
tor of coronary events, better than triglyc-
erides (3).
Most interesting, GGT was two times
lower for fibrates (36.7  24.4 units/l)
than for the two other groups (67.1 
71.3 units/l for statins, P  0.01 and
58.1  51.7 units/l in nontreated sub-
jects, P  0.01), taking into consideration
potential confounders, including alcohol
intake and triglycerides. GGT is often el-
evated in obese subjects and has been as-
sociated with steatosis, which could be
due to increased effects of insulin in the
liver and could contribute to the develop-
ment of systemic insulin resistance and
hyperinsulinemia in obesity. GGT was re-
ported as one of the independent predic-
tors of the metabolic syndrome and type 2
diabetes (1,4). Moreover, GGT was de-
tected in atheromatous plaques and has
been shown to promote LDL oxidation by
hydrolyzing glutathione into more potent
iron reductants (5). Thus, fibrates may
prove effective in the treatment of dyslip-
idemic diabetic or obese patients, since
they should improve the hepatic suffering
induced by the triglyceride load and also
limit the potential proatherogenic effects
of GGT.
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The hypothesis of a detrimental rolefor IGF-1 and other growth factorsin the development of vascular dis-
ease (1) has not been consistently sup-
ported by recent studies (2,3). New
evidence suggests that cellular senescence
(4) and impaired vascular endothelial
proliferation, adhesion, and incorpora-
tion play a pivotal role in the development
of macrovascular disease (5). Indeed, re-
cent data on large numbers suggest that
higher IGF-1 bioavailability may protect
against the onset of ischemic heart disease
(6,7) and glucose intolerance (8) and, in
type 2 diabetic patients, may offer im-
proved metabolic control and prevent
vascular complications (9,10). Other po-
tential beneficial actions of IGF-1 in car-
diovascular physiology include increased
nitric oxide synthesis and K channel
opening (11,12), and this may explain the
impaired small-vessel function associated
with low IGF-1 levels in patients with car-
diovascular syndrome X (12). By counter-
acting oxidized LDL-induced cytotoxicity
and vascular smooth muscle cell apopto-
sis, IGF-1 may protect against plaque in-
stability and rupture (2). In patients with
acute myocardial infarction, markedly re-
duced IGF-1 values are associated with a
worse outcome (13,14), and recent data
suggest that intramyocardial (15,16) or
vascular (17) gene delivery of growth fac-
tors can improve symptoms and exercise
capacity in patients with coronary or pe-
ripheral vascular disease.
We were therefore surprised by two
recent studies proposing IGF-1 as a me-
diator of harmful vascular effects (18,19).
The authors found an inverse association
between IGF binding protein (IGFBP)-1
and carotid intimal-medial thickness (r 
0.135, P  0.041) (18), macrovascular
disease (19), and hypertension (19) in pa-
tients with type 2 diabetes. IGFBP-1 is a
minor component of the system of
IGFBPs 1– 6, first discovered in the
1990s, and regulated by a complex group
of proteases and phosphatases (20). As
IGFBP-1 is generally assumed to inhibit
IGF-1 bioavailability (21), the authors
conclude that IGF-1 exerted harmful vas-
cular effect (18,19).
We propose two different interpreta-
tions of the above data, not necessarily
exclusive. First, the reduced IGFBP-1
concentration observed in situations of
vascular disease (18,19) could result from
activation of a compensatory mechanism
leading to higher IGF-1 bioavailability.
This interpretation is confirmed by the
finding in hypertensive patients of higher
IGF-1 levels than in control subjects (22),
and of a positive association among
IGF-1, insulin sensitivity, and preserved
vasodilator capacity (23,24). Indeed, in
these patients, IGF-1 was the main inde-
pendent predictor of both coronary re-
serve and insulin sensitivity (23). Second,
alternatively or additionally, one should
consider that the interaction between
IGF-1 and its binding proteins is com-
plex. An adequate serum amount of total
IGFBP-1 is essential for IGF-1’s biological
activity (8,25), independently of its phos-
phorilation status. Moreover, overexpres-
sion of IGFBP-1 attenuates IGF-1’s
growth-promoting actions in vitro but en-
hances them in vivo (26). Thus, a thresh-
old concentration of IGFBP-1 might
enhance, rather than impair, IGF-1’s bio-
activity through a partial agonism-like
action.
Because IGFBPs have been character-
ized only recently and their physiology in
humans is not completely understood, we
think further studies are needed to better
understand the true value of the IGF-1/
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Response to Conti et al.
W e thank Conti et al. (1) for theirinterest in our recent article (2)and the editor for the opportu-
nity to further discuss the role of the IGF
system in atherosclerosis.
We found an inverse relation between
IGF binding protein-1 (IGFBP-1) and ca-
rotid intima-media thickness (IMT) in
type 2 diabetic patients. In the linear re-
gression model for diabetic subjects with
cardiovascular disease (CVD), IGFBP-1
was one of the main determinants of IMT
(standardized coefficient 	  0.353,
P  0.027) together with age, Apo B, and
pulse pressure; other determinants were
diabetes duration, smoking, BMI, sex,
and lipoprotein [Lp(a)]. This model ex-
plained 57.3% of maximum IMT varia-
tion. IGFBP-1 also remained in the linear
regression model for IMT in subjects
without CVD. Our cross-sectional study
setting does not allow the interpretation
to which extent these associations are
causal. In agreement with previous data
(3), IGFBP-1 concentration was inversely
related to insulin resistance examined by
homeostasis model assessment.
On the contrary, after adjusting for
confounders, we found no association be-
tween total IGF-I and either IMT or pres-
ence of CVD. This indicates the relation
between IGFBP-1 and IMT to be indepen-
dent of IGF-I. Our results underline
IGFBP-1 as a marker of insulin resistance
and the metabolic syndrome, but this
cannot be extrapolated to reflect an IGF-I
effect on the vasculature. Similarly, Heald
et al. (4) demonstrated an inverse corre-
lation between IGFBP-1, but not IGF-I,
and clinical cardiovascular disease in type
2 diabetic subjects.
Another finding was the positive cor-
relation of total IGF-I with LDL choles-
terol and Lp(a) and IGFBP-3 with LDL
cholesterol, Lp(a), total cholesterol, and
Apo B after controlling for age, sex, BMI,
and diabetes duration. Thus, in hyper-
cholesterolemic diabetic patients the IGF
axis seems to be activated.
The relation of the IGF system to CVD
is complex and awaits a conclusive an-
swer after over 1,000 published articles
(5). Therefore, we agree with Conti et al.
that further research is needed to under-
stand the entire picture.
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Metformin in Type 1
Diabetes
Is this a good or bad idea?
The article by Meyer et al. (1) revivesa debate regarding the appropriate-ness of metformin use for people
with type 1 diabetes. Given the potential
for coexisting lactic acidosis and diabetic
ketoacidosis, how can one justify its use?
Indeed, there was little reason to expect a
benefit in patients who were studied:
nonobese type 1 diabetic subjects with
HbA1c 9.0% who were taking 0.7
units  kg insulin1  day1. A modest
average reduction of daily insulin require-
ments, 4.3 units, as compared with an in-
crease of 1.7 units for placebo, does not
seem to be worth the trade-off of in-
creased risk for severe hypoglycemia (19
events in metformin group vs. 8 events in
placebo group). There was no differential
effect in terms of HbA1c. Only 7 of 31
patients (23%) treated with metformin re-
sponded in terms of a significant (20%)
reduction in insulin requirement. Fur-
thermore, it is likely that the incidence of
hypoglycemia would be much greater if
more aggressive metabolic targets of
HbA1c had been applied. Despite the fail-
ure to observe diabetic ketoacidosis, the
limited number and short period of ob-
servation does not permit the conclusion
that metformin is safe in ketosis-prone di-
abetic subjects.
We have seen a number of type 1
diabetic patients who have received met-
formin prescriptions by other practitio-
ners. It appears that these prescriptions
were given because of a failure to identify
latent autoimmune diabetes in adults or
because the physician believed that the
potential for insulin dose reduction and
lipid improvement justified a putative
small risk for diabetic ketoacidosis and
lactic acidosis. The temptation to pre-
scribe metformin is increased because of
the high prevalence of metabolic syn-
drome among U.S. adults (2). Indeed, the
diagnosis of metabolic syndrome can fre-
quently be made in the type 1 diabetic
population. For example, using BMI as a
marker for metabolic syndrome, we ob-
served an average BMI of 27 kg/m2 in 343
consecutive subjects with type 1 diabetes;
this means that our average type 1 dia-
betic patient is overweight. A BMI 30
kg/m2, sufficient to diagnosis obesity, was
observed in 89 of 343 subjects (26%).
Seven of our type 1 diabetic patients had a
BMI 41 kg/m2. Of these severely obese
subjects, two were receiving metformin
therapy as well as insulin.
The results of the study by Meyer et
al. suggest that a small subset of type 1
diabetic patients benefit in terms of insu-
lin dose reduction when metformin is
added to insulin. Questions about long-
term safety and efficacy in this patient
population remain unanswered. There-
fore, when is it reasonable and defensible
to prescribe metformin in type 1 diabetes?
We suggest that metformin should be
avoided unless the following criteria are
met: 1) insulin resistence is clearly inter-
fering with satisfactory glucose control
despite lifestyle interventions; 2) the risk
of diabetic ketoacidosis is minimized by
an intensive program of insulin, self-
monitoring of blood glucose, urine ke-
tone measurement if blood glucose
exceeds 300 mg/dl, and regular medical
supervision; 3) the patient receives coun-
seling so that he or she understands the
potential risk for lactic acidosis; and 4)
efficacy is frequently evaluated to justify
continued use of metformin.
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Metformin and
Insulin in Type 1
Diabetes
The first step
T he insulin-sparing effect of met-formin and its positive effect on glu-cose metabolism is now well
documented in insulin-treated type 2 di-
abetic patients, although the mechanisms
of these effects are not overly clear (1). In
insulin-treated type 1 diabetic patients,
the use of metformin has only been as-
sessed in a few studies and, surprisingly,
the same insulin-sparing effect has been
found despite some methodological diffi-
culties. However, the clinical interest of
metformin in the treatment of type 1 dia-
betes has remained questionable. For the
first time, we have shown in a randomized
double-blind trial that metformin has an
insulin-sparing effect in type 1 diabetic
patients (even if the studied population
was not clinically insulin resistant) (2).
The selected patients were C-peptide
negative after intravenous glucagon injec-
tion and were not identified as having
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metabolic syndrome. The patients were
moderately overweight (BMI close to 25
kg/m2), and their daily insulin needs were
not greater than that seen for other type 1
diabetic patients. The insulin-sparing ef-
fect of metformin was obtained for basal
insulin needs but not for prandial needs.
Although no definitive explanation could
be given, it is now clear that the use of
metformin may be appropriate for some
type 1 diabetic patients.
Our study was designed to assess the
insulin-sparing effect of metformin in in-
sulin-treated type 1 diabetic patients, and
this end was achieved. However, it was
not designed to give clinical or biological
criteria of indications associated with
metformin use and insulin. We found that
a subset of patients had a reduction of at
least 20% in insulin requirements with
stable and satisfactory glucose control,
but a backward logistic regression did not
allow prediction criteria of a good re-
sponse to be defined. Thus, an expanded
study using selection criteria identified in
our previous study coupled with a larger
range of BMI or bodyweight and a larger
range of daily insulin doses in selected
patients must be performed to determine
therapeutic indications of this association
We believe that metformin use could
be beneficial in type 1 diabetic patients
who are overweight or obese, are receiv-
ing large doses of insulin, and have an
HbA1c 8%. The use of metformin could
be very useful in these patients but must
be carried out under clinical and biologi-
cal supervision to avoid complications
such as lactic acidosis, which remains ex-
ceptional in our experience of type 1 and
in type 2 diabetic patients.
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Response to Han et al.
W e read with great interest the ar-ticle by Han et al., which was re-cently published in Diabetes Care
(1). The authors studied the association
between baseline levels of C-reactive pro-
tein (CRP) and the 6-year incidence of the
metabolic syndrome and type 2 diabetes
in Mexican subjects. They found an odds
ratio (OR) of 4.1 (95% CI 2.1–8.0) for
developing the metabolic syndrome and
an OR of 5.4 (2.2–13.4) for incident type
2 diabetes among women in the highest
compared with the lowest tertile of CRP.
ORs were adjusted for age, smoking,
physical activity, and alcohol intake. In
men, no such association was found. Ad-
ditional adjustment for BMI slightly low-
ered the ORs; adjustment for waist-to-hip
ratio (WHR) did not.
We have studied baseline CRP levels
and their relation to incident type 2 dia-
betes in an age-, sex-, and glucose-
stratified sample of the Hoorn Study, a
population-based cohort study of glucose
tolerance among Caucasian people (2).
The study methods and follow-up dura-
tion are closely similar to the Mexico City
Diabetes Study (MCDS) described by Han
et al., except that our subjects were 15
years older at baseline. Glucose tolerance
status was assessed by a 75-g oral glucose
tolerance test at baseline and after 6.4
years of follow-up. CRP was measured in
plasma by high-sensitive enzyme-linked
immunosorbent assay, while information
was available on BMI, WHR, smoking,
and physical activity. Of the 140 men and
139 women who had follow-up measure-
ments and were free of diabetes at base-
line, 17.8% of the men and 20.9% of the
women developed diabetes. In contrast to
the findings of Han et al., we did not ob-
serve an association between baseline
CRP levels and incident diabetes in
women, while in men we found an OR of
3.0 (95% CI 1.0–9.3) in the highest com-
pared with the lowest tertile of CRP, after
adjustment for age (Table 1). Further ad-
justment for BMI, smoking, or physical
activity did not materially change these
results, while adding WHR to the model
substantially lowered the OR in men.
Thus, in the Hoorn Study, CRP is not a
very strong determinant of the develop-
ment of type 2 diabetes, in contrast to
WHR and impaired glucose metabolism
(3). We realize that our study sample of
279 subjects is much smaller than the
study presented by Han et al. (n  1,244).
The relationship in men, however, was
strong, whereas in the MCDS it was
strong only in women. In the previous
prospective study by Barzilay et al. (4) an
OR of 2.0 (1.4–2.9) was found when ex-
treme quartiles of CRP were compared.
They did not analyze men and women or
black and white subjects separately.
Pradhan et al. (5) found an OR of 4.2
(1.5–12.0) in women. Both studies did
not take WHR into account. Ethnicity
Table 1—Relative risk associated with high C-reactive protein (second and third tertile com-




2nd tertile 3rd tertile 2nd tertile 3rd tertile
1 Age 1.4 (0.4–4.8) 3.0 (1.0–9.3) 0.7 (0.3–2.1) 1.1 (0.4–3.0)
2 Model 1  BMI 1.4 (0.4–4.8) 3.0 (1.0–9.3) 0.6 (0.2–1.8) 0.9 (0.3–2.5)
3 Model 1  WHR 1.4 (0.4–4.8) 1.9 (0.6–6.4) 0.6 (0.2–1.7) 0.9 (0.3–2.5)
4 Model 1  smoking 1.3 (0.4–4.7) 2.9 (0.9–9.2) 0.7 (0.3–2.1) 1.2 (0.4–3.2)
5 Model 1  physical activity 1.4 (0.4–4.7) 3.0 (1.0–9.3) 0.7 (0.3–2.1) 1.1 (0.4–3.0)
Data are OR (95% CI).
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may also play an important role in ex-
plaining the inconsistent results.
In conclusion, we suggest caution in
the interpretation of the results because of
inconsistent findings, in particular be-
tween sexes. It is unclear why inflamma-
tion would be important in the patho-
genesis of type 2 diabetes only in women
or only in men.
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Prospective Relation
of C-Reactive Protein
With Type 2 Diabetes
Response to Snijder et al.
W e thank Snijder et al. (1) for theirinterest in our article (2) and forsharing their data relating C-re-
active protein (CRP) to the risk of diabetes
development in the Hoorn Study. We
readily agree that it is unclear why inflam-
mation might be more important to the
pathogenesis of type 2 diabetes in women
compared with men or indeed vice versa.
We have reanalyzed our CRP data using
the same covariates as Snijder et al. and
essentially our results are unchanged—
the relation between CRP and diabetes re-
mains strong in women, even after
inclusion of waist-to-hip ratio (WHR),
but is absent in men (Table 1). Interest-
ingly, on reanalysis of similarly relevant
data from the Insulin Resistance Athero-
sclerosis Study (IRAS) (3), a study of sim-
ilar size to the Mexico City Diabetes Study
(MCDS), the relation between baseline
CRP and diabetes development was also
stronger in women compared with men
using the same covariate adjustments
(data not shown). Moreover, in both the
MCDS and IRAS, adjustment for BMI at-
tenuated the link between CRP and dia-
betes more so than WHR.
One possibility of the divergent re-
sults could be the younger baseline age
(46 years) in MCDS in comparison to
that of the Hoorn study (61 years). In
this respect it is important to consider the
additional potential confounding influ-
ence of hormonal replacement therapy
(HRT) in women. HRT use increases CRP
concentrations in women (4), but para-
doxically recent data from the Heart and
Estrogen/Progestin Replacement Study
suggest that HRT reduces risk of diabetes
development by 35% (5). In MCDS, only
4% of women were on HRT at baseline
and hormonal use did not confound the
link between CRP and diabetes. However,
because of higher age, a potentially much
higher proportion of women in the Hoorn
Study may have been on HRT at baseline,
which could thus disguise any potential
association between CRP and diabetes
risk.
We acknowledge that our inability to
find an association between CRP and di-
abetes risk in men may simply be due to a
lack of power. A recent relevant study (6)
from the West of Scotland Coronary Pre-
vention Study (WOSCOPS) group that
included 127 new cases (predominantly
Caucasian) of diabetes reported a strong
association between baseline CRP and di-
abetes risk independent of BMI, blood
pressure, smoking, and fasting lipids and
glucose concentrations. Alternatively and
as Snijder et al. suggest, ethnicity may also
play a role in explaining inconsistent
results.
Clearly, further studies are needed to
examine the relation between inflamma-
Table 1—ORs (with 95% CIs) associated with high C-reactive protein (second and third tertile
compared to first tertile) for developing type 2 diabetes after 6.5 years of follow-up in the
Mexico City Diabetes Study
Model
Men
(35 incident cases/n  460)
Women









1 Age 0.7 (0.3–1.7) 1.0 (0.5–2.3) 3.1 (1.2–7.9)* 5.7 (2.3–13.9)†
2 Model 1  BMI 0.6 (0.2–1.4) 0.8 (0.4–1.9) 2.2 (0.9–5.8)* 3.1 (1.2–8.1)*
3 Model 1  WHR 0.6 (0.2–1.5) 0.9 (0.4–2.1) 3.0 (1.2–7.7)* 5.4 (2.2–13.3)†
4 Model 1  smoking 0.7 (0.3–1.7) 1.0 (0.5–2.3) 3.1 (1.2–8.0)* 5.7 (2.3–14.1)†
5 Model 1  physical
activity
0.7 (0.3–1.6) 0.9 (0.4–2.0) 2.7 (1.0–7.1)* 5.3 (2.2–13.2)†
The main effect of gender is significant (P  0.05) for each model. Gender-CRP tertile interaction: *P  0.05,
†P  0.01.
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tory markers and diabetes risk. It would
be useful if such studies were to report
associations separately in men and
women in order to enable identification of
any potential gender differences.
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Response to Tabaei and Herman
W e read the article by Tabaei andHerman (1) in the November2002 issue of Diabetes Care with
great interest and feel that it covers an
exciting and vital area of diabetes re-
search. We applaud the authors’ attempts
to improve current standards of diabetes
screening and the journal’s willingness to
publish important new findings in the
field. However, when we reviewed the ar-
ticle, we found the results difficult to re-
produce, especially as there were no
numerical examples provided in the text.
Using the precise formula given in the ar-
ticle, our calculations produced negative
probability values. We would therefore
like to take this opportunity to point out a
source of possible error in the equation
and clarify the logistic regression model.
The logistic regression model and the
“logit” model can be written as:
lnP/1  P)]  	0  	iXi  e (2)
where X  	0  	iXi are the coefficients
(parameters) for the linear predictor and
Xi represents the values of the explanatory
variables (we have assumed that these co-
efficients have been correctly estimated in
the article); ln is the natural logarithm,
logexp, where exp  2.71828. . . ; P is the
probability that the event “previously un-
diagnosed diabetes” occurs; P/(1  P) is
the “odds ratio”; and ln[P/(1  P)] is the
log odds ratio, or “logit.”
In contrast to the simple linear prob-
ability model (Y  a  bX  e), the logit
distribution constrains the estimated
probabilities to lie between 0 and 1. For
instance, the estimated probability is:
P  [exp(	0  	iXi)]/[1  exp(	0  	iXi)]
or
P  1/[1  exp (	0  	iXi)]
For a 45-year-old man with a BMI of
29 kg/m2, a plasma glucose level of 125
mg/dl, and a postprandial time of 3 h, the
probability calculated with the published
formula would be P  0.0555 (i.e. P 
0). This result does not match the require-
ment for probabilities to lie between 0 and
1. For the same case, but with the cor-
rected formula, the probability of being
previously undiagnosed for diabetes is
P  0.04996.
Details of the calculation with the
formula published in the article:
P  1/[1  exp(X)]
X  10.0382  0.0331*(age  45
years)  0.0308*(plasma glucose  125
mg/dl)  0.25*(postprandial time  3 h)
 0.562*(sex  0)  0.0346*(BMI  29
kg/m2). X  2.9453 and P  1/[1 
exp(X)]  1/(1  exp(2.9453)  1/(1 
19.01636644)  1/18.01636644. P 
0.0555.
Details of the calculation with the
corrected formula:
P  1/[1  exp(X)]
X  2.9453; P  1/[1  exp(X)] 
1/ (1  exp[2 .9453])  1/ (1 
19.01636644)  1/20.01636644; P 
0.04996.
Therefore, we would suggest that the
following equations should be used:
X  10.0382  0.0331*(age)  0.0308*
(plasma glucose)  0.25* (postprandial
time)  0.562 (if female)  0.0346* (BMI)
and P  1/[1  exp(X)]
We hope these comments serve to
clarify this logistic regression equation to
screen for diabetes and, in conjunction
with the valuable work of our colleagues
Drs. Tabaei and Herman, help expand the
knowledge base in this key area of diabe-
tes research.
STÉPHANE ROZE, MSC
ANDREW J. PALMER, BSC, MBBS
WILLIAM J. VALENTINE, PHD
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Response to Roze, Palmer, and
Valentine
W e would like to thank Roze,Palmer, and Valentine (1) fortheir careful reading of our arti-
cle (2) entitled “A multivariate logistic
regression to screen for diabetes: develop-
ment and validation.” The estimated
probability formula for the logistic regres-
sion model was indeed misprinted with a
minus sign. The correct estimated proba-
bility formula is:
P  1/(1  ex), where x 
10.0382  [0.0331 (age in years) 
0.0308 (random plasma glucose in mg/
dl)  0.2500 (postprandial time assessed
as 0 to 8 hours)  0.5620 (if female) 
0.0346 (BMI)].
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Obesity in Type 2
Diabetes
Response to van Tilburg et al.
W e read with interest the observa-tion letter by van Tilburg et al.(1) reporting that the Glu27Gln
polymorphism of the 	2-adrenergic re-
ceptor (B2ADR) has no important effect
on BMI, metabolic control, or plasma lip-
ids. However, the authors did not men-
tion the physical activity and diet regimen
in their study. B2ADR is a major lipolytic
receptor in human adipocytes, activated
by catecholamines especially during a
weight reduction regimen. Meirhaeghe et
al. (2) reported that B2ADR Glu27Gln
polymorphism is significantly associated
with obesity in individuals who do not
have regular physical activity, while no
effect of such polymorphism is found in
those who do have physical activity, and
suggested that obese individuals with
B2ADR Glu27Gln genotype may benefit
from physical activity to reduce their body
weight. We also demonstrated the same as-
sociation between another B2ADR poly-
morphism (Arg16Gly) and obesity in
individuals treated with a combined low-
energy diet and exercise regimen (3). There-
fore, the authors should have further
divided the subjects according to the degree
of their physical activity and analyzed the
data, because body weight and body fat or
metabolic control are influenced by physi-
cal activity and dietary changes, especially
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Obesity in Type 2
Diabetes
Response to Yoshioka, Yoshida,
and Yoshikawa
W e recently reported that ourgroup (n  502) of type 2 dia-betic subjects did not reveal sta-
tistically significant differences in BMI
with respect to the three groups of carriers
of 	2-adrenergic receptor polymor-
phisms (1). Meirhaghe et al. (1) report
that in men not participating in physical
activity, Gln27Gln carriers had a higher
BMI than the Glu27 (combined heterozy-
gous and homozygous) carriers (27.2 
0.4 vs. 25.2  0.3 kg/m2), while no effect
on BMI was found in the men not partic-
ipating in physical activity.
We have not collected data on the
physical activity of our subjects. How-
ever, taking into account that our subjects
had a mean age of 61  9 years (roughly
10 years older than the subjects reported
by Meirhaghe et al.), we suspect that the
vast majority of them do not participate in
much physical activity. In any case, their
physical activity is presumably less than
that of the subjects studied by Meirhaghe
et al. Much to our surprise, we actually
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find the opposite, which is a lower (and
not a higher!) BMI (27.2  3.8) in the
Gln27Gln carriers compared with the
others (27.9  4.4 for Gln27Glu and
28.2  4.0 kg/m2 for Glu27Glu), al-
though the differences did not attain sta-
tistical significance. These findings were
similar for men and women when taken
together or separately.
Obviously, there are two major differ-
ences between these two studies. The sub-
jects in our study (2) had type 2 diabetes
and were considerably older. Whether
these two differences explain the diver-
gent findings of the study of Meirhaghe et
al. and our study is uncertain. However,
the suggestion by van Tilburg et al. that, if
anything, the BMI was lower (and not
higher) in the Gln27Gln27 group might
point to a chance finding in the studies by
Meirhaghe et al. As for the observations
regarding the Arg16Gly polymorphism,
we have not studied this polymorphisms
in our group of subjects.
It has become more and more clear
that association studies of a particular
polymorphism with a certain physiologi-
cal parameter are often hard to replicate;
this necessitates the need to perform rep-
lication studies before a finding can be
regarded as truly positive.
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